Two Phase III trials show Tradjenta (Boehringer/Eli Lilly) improves glucose control in Asian patients with Type 2 Diabetes

Results from two Phase III studies of Tradjenta (linagliptin), from Boehringer/Eli Lilly, shows that it improved blood glucose control in Asian patients with Type 2 Diabetes. In the first study, linagliptin monotherapy demonstrated a 0.68% reduction in HbA1c (from a mean baseline HbA1c of 7.95%) at 24 weeks among Asian patients from China, Malaysia, and the Philippines, compared with a reduction of 0.18% with placebo.

Results from the second study showed an HbA1c reduction of 0.66% (from a mean baseline HbA1c of 7.99%) at 24 weeks among Asian patients who received linagliptin added to metformin at 24 weeks, versus a reduction of 0.14% in the placebo arm. In both studies, the incidence of adverse events was similar. The data were presented at the American Diabetes Association 73rd Scientific Sessions.